
Laura Turunen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7311894/publications.pdf Version: 2024-02-01



LALIDA TUDUNEN

#	Article	IF	CITATIONS
1	iTReX: Interactive exploration of mono- and combination therapy dose response profiling data. Pharmacological Research, 2022, 175, 105996.	7.1	11
2	Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia. Cancer Discovery, 2022, 12, 388-401.	9.4	73
3	Patient-tailored design for selective co-inhibition of leukemic cell subpopulations. Science Advances, 2021, 7, .	10.3	28
4	High-throughput compound screening identifies navitoclax combined with irradiation as a candidate therapy for HPV-negative head and neck squamous cell carcinoma. Scientific Reports, 2021, 11, 14755.	3.3	7
5	Human Tumor–Derived Matrix Improves the Predictability of Head and Neck Cancer Drug Testing. Cancers, 2020, 12, 92.	3.7	20
6	Drug screening approach combines epigenetic sensitization with immunochemotherapy in cancer. Clinical Epigenetics, 2019, 11, 192.	4.1	1
7	Methods for High-throughput Drug Combination Screening and Synergy Scoring. Methods in Molecular Biology, 2018, 1711, 351-398.	0.9	140
8	Expanding the Utility of Midostaurin in Acute Myeloid Leukemia - Predictive Mutational Signatures in Patient Samples without FLT3 mutations and Clinically Applicable Synergistic Drug Combinations. Blood, 2018, 132, 2743-2743.	1.4	0
9	Antiviral Properties of Chemical Inhibitors of Cellular Anti-Apoptotic Bcl-2 Proteins. Viruses, 2017, 9, 271.	3.3	39
10	Precision Cancer Medicine in the Acoustic Dispensing Era: Ex Vivo Primary Cell Drug Sensitivity Testing. Journal of the Association for Laboratory Automation, 2016, 21, 27-36.	2.8	22
11	Systematic Mapping of Kinase Addiction Combinations in Breast Cancer Cells by Integrating Drug Sensitivity and Selectivity Profiles. Chemistry and Biology, 2015, 22, 1144-1155.	6.0	22
12	Utilization of in situ ELISA method for examining Trk receptor phosphorylation in cultured cells. Journal of Neuroscience Methods, 2014, 222, 142-146.	2.5	17
13	Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia. Cancer Discovery, 2013, 3, 1416-1429.	9.4	334
14	Identification Of AML Subtype-Selective Drugs By Functional Ex Vivo Drug Sensitivity and Resistance Testing and Genomic Profiling. Blood, 2013, 122, 482-482.	1.4	0
15	Development of a Cancer Pharmacopeia-Wide Ex-Vivo Drug Sensitivity and Resistance Testing (DSRT) Platform: Identification of MEK and mTOR As Patient-Specific Molecular Drivers of Adult AML and Potent Therapeutic Combinations with Dasatinib. Blood, 2011, 118, 2487-2487.	1.4	0
16	A Structural Insight into the Molecular Recognition of a (â^')-Δ9-Tetrahydrocannabinol and the Development of a Sensitive, One-Step, Homogeneous Immunocomplex-Based Assay for Its Detection. Journal of Molecular Biology, 2010, 400, 803-814.	4.2	12
17	Automated Panning and Screening Procedure on Microplates for Antibody Generation from Phage Display Libraries. Journal of Biomolecular Screening, 2009, 14, 282-293.	2.6	55